Iron Boosts Antitumor Type 1 T-cell Responses and Anti-PD1 Immunotherapy

Area of Science:

• Immunology
• Oncology
• Metabolic pathways

Background:

• Cancer immune evasion necessitates restoring T-cell function, particularly interferon-gamma (IFNγ) production.
• Immunotherapies like anti-PD1 improve outcomes but lack efficacy in some patients, highlighting the need for combination strategies.

Purpose of the Study:

• To investigate the impact of iron supplementation on T-cell responses and its potential to enhance cancer immunotherapy.
• To explore the mechanisms underlying iron's effects on T cells and antitumor activity.

Main Methods:

• In vivo and in vitro experiments assessing T-cell responses, including IFNγ production and metabolic profiles.
• Tumor cell line transplantation in mice to evaluate the effect of iron supplementation and anti-PD1 immunotherapy.

Main Results:

• Iron supplementation significantly enhanced T-cell responses, characterized by increased IFNγ production and a metabolic shift towards lipid oxidation.
• Iron supplementation demonstrated an "adjuvant" effect, slowing tumor growth and improving the efficacy of anti-PD1 immunotherapy in mice.
• Plasma ferritin levels correlated with antitumor response quality in patients receiving anti-PD1 immunotherapy.

Conclusions:

• Iron supplementation can reactivate antitumor immune responses by boosting T-cell function.
• Combining iron supplementation with anti-PD1 immunotherapy shows promise for improving cancer treatment efficacy.
• Plasma ferritin may serve as a biomarker for predicting response to anti-PD1 immunotherapy.